Cargando…

whISOBAX(TM) Inhibits Bacterial Pathogenesis and Enhances the Effect of Antibiotics

As bacteria are becoming more resistant to commonly used antibiotics, alternative therapies are being sought. whISOBAX (WH) is a witch hazel extract that is highly stable (tested up to 2 months in 37 °C) and contains a high phenolic content, where 75% of it is hamamelitannin and traces of gallic aci...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasooly, Reuven, Choi, Hwang-Yong, Do, Paula, Morroni, Gianluca, Brescini, Lucia, Cirioni, Oscar, Giacometti, Andrea, Apostolidis, Emmanouil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277200/
https://www.ncbi.nlm.nih.gov/pubmed/32438609
http://dx.doi.org/10.3390/antibiotics9050264
_version_ 1783543068869263360
author Rasooly, Reuven
Choi, Hwang-Yong
Do, Paula
Morroni, Gianluca
Brescini, Lucia
Cirioni, Oscar
Giacometti, Andrea
Apostolidis, Emmanouil
author_facet Rasooly, Reuven
Choi, Hwang-Yong
Do, Paula
Morroni, Gianluca
Brescini, Lucia
Cirioni, Oscar
Giacometti, Andrea
Apostolidis, Emmanouil
author_sort Rasooly, Reuven
collection PubMed
description As bacteria are becoming more resistant to commonly used antibiotics, alternative therapies are being sought. whISOBAX (WH) is a witch hazel extract that is highly stable (tested up to 2 months in 37 °C) and contains a high phenolic content, where 75% of it is hamamelitannin and traces of gallic acid. Phenolic compounds like gallic acid are known to inhibit bacterial growth, while hamamelitannin is known to inhibit staphylococcal pathogenesis (biofilm formation and toxin production). WH was tested in vitro for its antibacterial activity against clinically relevant Gram-positive and Gram-negative bacteria, and its synergy with antibiotics determined using checkerboard assays followed by isobologram analysis. WH was also tested for its ability to suppress staphylococcal pathogenesis, which is the cause of a myriad of resistant infections. Here we show that WH inhibits the growth of all bacteria tested, with variable efficacy levels. The most WH-sensitive bacteria tested were Staphylococcus epidermidis, Staphylococcus aureus, Enterococcus faecium and Enterococcus faecalis, followed by Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Streptococcus agalactiae and Streptococcus pneumoniae. Furthermore, WH was shown on S. aureus to be synergistic to linezolid and chloramphenicol and cumulative to vancomycin and amikacin. The effect of WH was tested on staphylococcal pathogenesis and shown here to inhibit biofilm formation (tested on S. epidermidis) and toxin production (tested on S. aureus Enterotoxin A (SEA)). Toxin inhibition was also evident in the presence of subinhibitory concentrations of ciprofloxacin that induces pathogenesis. Put together, our study indicates that WH is very effective in inhibiting the growth of multiple types of bacteria, is synergistic to antibiotics, and is also effective against staphylococcal pathogenesis, often the cause of persistent infections. Our study thus suggests the benefits of using WH to combat various types of bacterial infections, especially those that involve resistant persistent bacterial pathogens.
format Online
Article
Text
id pubmed-7277200
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72772002020-06-15 whISOBAX(TM) Inhibits Bacterial Pathogenesis and Enhances the Effect of Antibiotics Rasooly, Reuven Choi, Hwang-Yong Do, Paula Morroni, Gianluca Brescini, Lucia Cirioni, Oscar Giacometti, Andrea Apostolidis, Emmanouil Antibiotics (Basel) Article As bacteria are becoming more resistant to commonly used antibiotics, alternative therapies are being sought. whISOBAX (WH) is a witch hazel extract that is highly stable (tested up to 2 months in 37 °C) and contains a high phenolic content, where 75% of it is hamamelitannin and traces of gallic acid. Phenolic compounds like gallic acid are known to inhibit bacterial growth, while hamamelitannin is known to inhibit staphylococcal pathogenesis (biofilm formation and toxin production). WH was tested in vitro for its antibacterial activity against clinically relevant Gram-positive and Gram-negative bacteria, and its synergy with antibiotics determined using checkerboard assays followed by isobologram analysis. WH was also tested for its ability to suppress staphylococcal pathogenesis, which is the cause of a myriad of resistant infections. Here we show that WH inhibits the growth of all bacteria tested, with variable efficacy levels. The most WH-sensitive bacteria tested were Staphylococcus epidermidis, Staphylococcus aureus, Enterococcus faecium and Enterococcus faecalis, followed by Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Streptococcus agalactiae and Streptococcus pneumoniae. Furthermore, WH was shown on S. aureus to be synergistic to linezolid and chloramphenicol and cumulative to vancomycin and amikacin. The effect of WH was tested on staphylococcal pathogenesis and shown here to inhibit biofilm formation (tested on S. epidermidis) and toxin production (tested on S. aureus Enterotoxin A (SEA)). Toxin inhibition was also evident in the presence of subinhibitory concentrations of ciprofloxacin that induces pathogenesis. Put together, our study indicates that WH is very effective in inhibiting the growth of multiple types of bacteria, is synergistic to antibiotics, and is also effective against staphylococcal pathogenesis, often the cause of persistent infections. Our study thus suggests the benefits of using WH to combat various types of bacterial infections, especially those that involve resistant persistent bacterial pathogens. MDPI 2020-05-19 /pmc/articles/PMC7277200/ /pubmed/32438609 http://dx.doi.org/10.3390/antibiotics9050264 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rasooly, Reuven
Choi, Hwang-Yong
Do, Paula
Morroni, Gianluca
Brescini, Lucia
Cirioni, Oscar
Giacometti, Andrea
Apostolidis, Emmanouil
whISOBAX(TM) Inhibits Bacterial Pathogenesis and Enhances the Effect of Antibiotics
title whISOBAX(TM) Inhibits Bacterial Pathogenesis and Enhances the Effect of Antibiotics
title_full whISOBAX(TM) Inhibits Bacterial Pathogenesis and Enhances the Effect of Antibiotics
title_fullStr whISOBAX(TM) Inhibits Bacterial Pathogenesis and Enhances the Effect of Antibiotics
title_full_unstemmed whISOBAX(TM) Inhibits Bacterial Pathogenesis and Enhances the Effect of Antibiotics
title_short whISOBAX(TM) Inhibits Bacterial Pathogenesis and Enhances the Effect of Antibiotics
title_sort whisobax(tm) inhibits bacterial pathogenesis and enhances the effect of antibiotics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277200/
https://www.ncbi.nlm.nih.gov/pubmed/32438609
http://dx.doi.org/10.3390/antibiotics9050264
work_keys_str_mv AT rasoolyreuven whisobaxtminhibitsbacterialpathogenesisandenhancestheeffectofantibiotics
AT choihwangyong whisobaxtminhibitsbacterialpathogenesisandenhancestheeffectofantibiotics
AT dopaula whisobaxtminhibitsbacterialpathogenesisandenhancestheeffectofantibiotics
AT morronigianluca whisobaxtminhibitsbacterialpathogenesisandenhancestheeffectofantibiotics
AT brescinilucia whisobaxtminhibitsbacterialpathogenesisandenhancestheeffectofantibiotics
AT cirionioscar whisobaxtminhibitsbacterialpathogenesisandenhancestheeffectofantibiotics
AT giacomettiandrea whisobaxtminhibitsbacterialpathogenesisandenhancestheeffectofantibiotics
AT apostolidisemmanouil whisobaxtminhibitsbacterialpathogenesisandenhancestheeffectofantibiotics